Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 301–400 of 1,003
Zarrinpar, A., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 103
Is It Time to Use Probiotics to Prevent or Treat Obesity?
Brusaferro, A., Cozzali, R., Orabona, C., Biscarini, A., Farinelli, E., Cavalli, E., Grohmann, U., Principi, N., & Esposito, S. (2018) · Nutrients · doi:10.3390/nu10111613 · Cited by 103
“These two gut hormones reduce gut motility [50], promote satiety, and suppress energy intake [51].”
BackgroundSuccessful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Self-citationA Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Katsurada, K., Maejima, Y., Nakata, M., Kodaira, M., Suyama, S., Iwasaki, Y., Kario, K., & Yada, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.116 · Cited by 112
GLP‐1 (9–36) Amide, Cleavage Product of GLP‐1 (7–36) Amide, Is a Glucoregulatory Peptide
Elahi, D., Egan, J. M., Shannon, R. P., Meneilly, G. S., Khatri, A., Habener, J. F., & Andersen, D. K. (2008) · Obesity · doi:10.1038/oby.2008.229 · Cited by 101
“Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.”
BackgroundInfluentialGLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 113
Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects
Kong, M., Chapman, I. M., Goble, E., Wishart, J. M., Wittert, G., Morris, H. A., & Horowitz, M. (1999) · Peptides · doi:10.1016/s0196-9781(99)00006-6 · Cited by 102
“Despite the results of a recent study in which IV administration of GLP-1 resulted in a modest suppression of appetite in normal volunteers [10], the absence of a differential effect of glucose and fructose on food intake in the present study is further, albeit indirect, evidence against an important physiological rol…”
BackgroundResultGlucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation
Trapp, S., & Cork, S. C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00333.2015 · Cited by 100
Sørensen, L. B., Flint, A., Raben, A., Hartmann, B., Holst, J. J., & Astrup, A. V. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802247 · Cited by 107
Self-citationIs glucagon-like peptide 1 an incretin hormone?
Nauck, M. A. (1999) · Diabetologia · doi:10.1007/s001250051165 · Cited by 112
“In healthy volunteers receiving an intravenous infusion of GLP-1, satiety was rated higher than with placebo and caloric intake during a second meal was considerably reduced [50].”
BackgroundNovel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 112
“Weight problem 2weight gain or even weight loss Yes No Obesity (weight gain) (peripheral insulin induces weight gain, but not in case of incretins) 2Food intake, 2body weight (Flint et al., 1998; Näslund et al., 1999a; Verdich et al., 2001; Zander et al., 2002) Yes”
BackgroundDiabesity and antidiabetic drugs
Pappachan, J. M., Fernandez, C. J., & Chacko, E. C. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.10.004 · Cited by 108
Liraglutide: the therapeutic promise from animal models
Knudsen, L. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02499.x · Cited by 99
Glucagon-like peptide-1 (7–36) amide: a central regulator of satiety and interoceptive stress
van Dijk, G., & Thiele, T. E. (1999) · Neuropeptides · doi:10.1054/npep.1999.0053 · Cited by 107
Meneilly, G. S., Greig, N., Tildesley, H., Habener, J. F., Egan, J. M., & Elahi, D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2835 · Cited by 99
Krog-Mikkelsen, I., Hels, O. H., Tetens, I., Holst, J. J., Andersen, J. R., & Bukhave, K. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.014225 · Cited by 110
“In experiments documenting the effect, the increase has been 200–400% (30).”
BackgroundSelf-citationGenetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk
Seidelmann, S. B., Feofanova, E., Yu, B., Franceschini, N., Claggett, B., Kuokkanen, M., Puolijoki, H., Ebeling, T., Perola, M., Salomaa, V., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.061 · Cited by 97
“This finding may be mediated by bacterial fermentation of luminal glucose to short-chain-fatty-acids that trigger GLP-1 secretion (25,27), leading to beneficial effects such as decreased appetite and improved cardiac function (28,29).”
BackgroundBurcelin, R., & Gourdy, P. (2017) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 94
“Infusions of native GLP-1 have been shown to reduce appetite in humans (27), and the once-daily GLP-1RA liraglutide 3.”
BackgroundGLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 95
Self-citationScrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
“The short term inhibitory effects of GLP-1 on food intake have recently been extended to human subjects, as normal volunteers receiving GLP-1 by iv infusion experienced enhanced sensations of increased satiety in association with decreased food intake (33).”
BackgroundNuts and healthy body weight maintenance mechanisms.
Mattes, R. D., & Dreher, M. L. (2010) · PubMed · Cited by 113
Ellrichmann, M., Kapelle, M., Ritter, P. R., Holst, J. J., Herzig, K.-H., Schmidt, W. E., Schmitz, F., & Meier, J. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0924 · Cited by 94
Self-citationLiraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95
“As well as stimulating insulin secretion in a glucose-dependent manner, the biological actions of GLP-1 in control subjects and patients with Type 2 diabetes mellitus include: glucose-dependent suppression of glucagon secretion [13,14]; reduction in appetite and food intake [15]; deceleration of gastric emptying [16,1…”
BackgroundGlucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94
Exendin-4 decreases amphetamine-induced locomotor activity
Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 95
“GLP-1 has been suggested to be associated with the satiety response following food consumption [20, 37] and activating GLP-1 receptors may induce a resting behavior that is similar to that observed during satiety after feeding [38].”
ResultHisadome, K., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Diabetes · doi:10.2337/db11-0489 · Cited by 97
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Steinert, R. E., Poller, B., Castelli, M., Drewe, J., & Beglinger, C. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29663 · Cited by 107
“Oral GLP-1 (2 mg) induced a significant 14% reduction in calorie intake; this is in keeping with early data by Flint et al (11), who reported that GLP-1 infusions enhance satiety and fullness and reduce spontaneous energy intake during a test lunch by 12% (12).”
ResultInteraction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men
Gutzwiller, J.-P., Degen, L., Matzinger, D., Prestin, S., & Beglinger, C. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00599.2003 · Cited by 94
“GLP-1 and CCK have previously been reported to reduce food intake and appetite in humans (6, 19, 20); the present results with individual hormone application confirm these previous results.”
BackgroundResultNewer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110
Integration of Satiety Signals by the Central Nervous System
Chambers, A. P., Sandoval, D. A., & Seeley, R. J. (2013) · Current Biology · doi:10.1016/j.cub.2013.03.020 · Cited by 90
“Peripheral or intracerebroventricular chronic treatment with long-acting pharmacological GLP-1 analogues, such as exendin-4 and liraglutide, increase intermeal intervals [52] and produce significant weight loss in rodents [41] and humans [53].”
Feltrin, K. L., Patterson, M., Ghatei, M. A., Bloom, S. R., Meyer, J. H., Horowitz, M., & Feinle‐Bisset, C. (2006) · Peptides · doi:10.1016/j.peptides.2006.01.023 · Cited by 108
Raun, K., von Voss, P., & Knudsen, L. B. (2007) · Obesity · doi:10.1038/oby.2007.204 · Cited by 93
“GLP-1 was originally shown to be a potent inhibitor of feeding when administered intracerebroventricularly to rats (8,9) and was later shown to promote fullness and satiety (10,11) and weight loss in humans (2,12).”
BackgroundIncretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 105
“Also, the central nervous GLP-1 effects on satiety and food intake are comparable in patients with diabetes and in healthy subjects [ 50 ,51].”
BackgroundKrieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
“Third, peripheral injections of GLP-1 at physiological doses reduce meal size [16,20–23] without inducing avoidance in rodents [18] and in the absence of malaise in humans [20,21,24,25].”
Recent advances in clinical practice challenges and opportunities in the management of obesity
Acosta, A., Abu Dayyeh, B. K., Port, J. D., & Camilleri, M. (2014) · Gut · doi:10.1136/gutjnl-2013-306235 · Cited by 91
Chapman, I. M. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2007.06.001 · Cited by 112
Decreased Glucagon‐like Peptide 1 Release after Weight Loss in Overweight/Obese Subjects
Adam, T. C. M., Jocken, J., & Westerterp‐Plantenga, M. S. (2005) · Obesity Research · doi:10.1038/oby.2005.80 · Cited by 91
Weight maintenance: challenges, tools and strategies for primary care physicians
Soleymani, T., Daniel, S., & Garvey, W. T. (2016) · Obesity Reviews · doi:10.1111/obr.12322 · Cited by 91
Inoue, K., Maeda, N., Kashine, S., Fujishima, Y., Kozawa, J., Hiuge-Shimizu, A., Okita, K., Imagawa, A., Funahashi, T., & Shimomura, I. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-109 · Cited by 89
“Several studies have demonstrated that GLP-1 promotes satiety and suppresses energy intake both in animals [23,24] and human subjects [25-28], however, the effect of liraglutide on eating behavior has not been examined in human type 2 diabetics.”
Endocrinology of anorexia of ageing
Chapman, I. M. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.02.004 · Cited by 77
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J., & Drucker, D. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 88
“To address the effectiveness of GLP-1 in the setting of obesity, GLP-1 was administrated to normal and obese human subjects in short-term infusion studies where it enhanced satiety and decreased energy intake [145, 146].”
BackgroundSchlögl, H., Kabisch, S., Horstmann, A., Lohmann, G., Müller, K., Lepsien, J., Busse-Voigt, F., Kratzsch, J., Pleger, B., Villringer, A., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1925 · Cited by 88
“Exenatide is a long-lasting glucagonlike peptide-1 (GLP-1) receptor agonist approved for the treatment of diabetes mellitus type 2 (T2D) (1,2).”
BackgroundPeripheral tissue–brain interactions in the regulation of food intake
López, M., Tovar, S. A., Vazquez, M. J., Williams, L. M., & Diéguez, C. (2007) · Proceedings of The Nutrition Society · doi:10.1017/s0029665107005368 · Cited by 98
“The anorectic effect of GLP-1 and OXM is also present in man (Flint et al. 1998, 2000, 2001; Gutzwiller et al. 1999; Naslund et al. 1999; Verdich et al. 2001; Meier et al. 2002).”
BackgroundOxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
“Again both of the “parent” peptides, glucagon and GLP-1, have effects on appetite and food intake [53,54].”
Self-citationJensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86
Kadowaki, T., & Kondo, K. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12092 · Cited by 86
Undernutrition and Anorexia in the Older Person
Visvanathan, R., & Chapman, I. M. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.06.009 · Cited by 100
Howarth, N. C., Saltzman, E. J., McCrory, M. A., Greenberg, A. S., Ausman, L. M., Kramer, D. G., Roberts, S. B., & Dwyer, J. T. (2003) · Journal of Nutrition · doi:10.1093/jn/133.10.3141 · Cited by 97
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 84
“In both animals and humans, GLP-1 enhances satiety (Tang-Christensen et al., 1996; Turton et al., 1996; Flint et al., 1998; Näslund et al., 1998; Williams et al., 2009; Kanoski et al., 2011; Renner et al., 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998;…”
BackgroundGlucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion
Hagemann, D., Holst, J. J., Gethmann, A., Banasch, M., Schmidt, W. E., & Meier, J. J. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.03.002 · Cited by 103
Self-citationPannacciulli, N., Bunt, J. C., Koška, J., Bogardus, C., & Krakoff, J. A. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.556 · Cited by 100
“When administered intravenously in men, GLP-1 enhanced satiety and reduced energy intake (3).”
BackgroundDo GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83
“However, subjective ratings of taste, visual appeal, smell, aftertaste, and overall palatability of test meals did not differ on two experimental days [31].”
BackgroundDPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Deacon, C. (2008) · Frontiers in Bioscience · doi:10.2741/2799 · Cited by 80
Eto, T., Inoue, S., & Kadowaki, T. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01662.x · Cited by 82
Bergenstal, R., Lewin, A., Bailey, T., Chang, D., Gylvin, T., Roberts, V., & for the NovoLog Mix-vs.-Exenatide Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 83
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes
Egan, J. M., Meneilly, G. S., & Elahi, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2002 · Cited by 82
“GLP-1 has been reported to decrease food intake with short-term administration (7, 9, 25, 26) but not with longer administration.”
BackgroundLEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100582 · Cited by 81
“concentration of GLP-1) in healthy, normal-weight, young men resulted in a similar reduction in energy intake of 12% during a comparable ad libitum meal test.(23) Interestingly, the appetite-suppressing effect of LEAP2 was reproduced in wild-type mice, but not in GHSR-null mice, showing that the GHSR is required for t…”
BackgroundSelf-citationLingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care · doi:10.2337/dc17-2381 · Cited by 81
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Jiao, A., Yu, B., He, J., Yu, J., Zheng, P., Luo, Y., Luo, J., Yan, H., Wang, Q., Wang, H., et al. (2021) · Nutrition · doi:10.1016/j.nut.2021.111198 · Cited by 90
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 79
“Hindawi Publishing Corporation Experimental Diabetes Research Volume 2012, Article ID 470851, 12 pages doi:10.1155/2012/470851”
BackgroundInfluentialFeinle, C., Chapman, I. M., Wishart, J. M., & Horowitz, M. (2002) · Peptides · doi:10.1016/s0196-9781(02)00087-6 · Cited by 89
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 81
“5 h) suppresses appetite, as recently reported in healthy young men (40) with similar characteristics as those in the present study.”
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Oral glucose intake inhibits hypothalamic neuronal activity more effectively than glucose infusion
Smeets, P. A. M., Vidarsdottir, S., de Graaf, C., Stafleu, A., van Osch, M. J. P., Viergever, M. A., Pijl, H., & van der Grond, J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00231.2007 · Cited by 79
“Of particular relevance to the present findings, GLP-1, OXM, and PYY act in the hypothalamus to induce satiety in rodents and humans (1, 2, 9, 10, 15, 39).”
BackgroundHansen, L., Hartmann, B., Mineo, H., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.021 · Cited by 93
Self-citationEffects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78
“Furthermore, GLP-1 also improves alpha-cell glucose sensing in patients with T2D and controls food intake by increasing satiety in these patients (Flint et al., 1998; Gutzwiller et al., 1999; Dunning et al., 2005).”
BackgroundSaxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Cobble, M. E., & Frederich, R. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-6 · Cited by 78
“Dipeptidyl peptidase-4 is the enzyme that rapidly deactivates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide [11,12]; these incretin hormones, secreted from the gut in response to food intake, decrease postprandial glucose levels by stimulating insulin secretion, inhibiting glucagon s…”
BackgroundTibaduiza, E. C., Chen, C., & Beinborn, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106692200 · Cited by 78
Baggio, L. (2000) · Endocrinology · doi:10.1210/en.141.10.3703 · Cited by 79
“Taken together with effects on reduction in food intake (30, 31), it seems that GLP-1 exerts both incretin and nonincretin mediated actions that contribute to glucoselowering in vivo.”
BackgroundThe incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
Self-citationMeier, J. J., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00289.2007 · Cited by 77
“, on gastric emptying and energy homeostasis (11, 21), one would not expect any differences in the hepatocyte response to incretin hormones at various glucose levels.”
BackgroundSelf-citationGrau, K., Cauchi, S., Holst, C., Astrup, A. V., Martínez, J. A., Saris, W. H. M., Blaak, E. E., Oppert, J., Arner, P., Rössner, S., et al. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27947 · Cited by 79
Self-citationDecara, J., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2018) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 76
“Concerning feeding, GLP-1 plays physiological roles in the regulation of food intake by acting centrally as an anorexigenic neurotransmitter and peripherally as a postprandial satiety hormone.(41,42) Central (1-3 nmol or 1-10 lg) or intravenous (600 pmol kg 1 min (1)) administration of GLP-1 in rodents and humans sign…”
BackgroundMetabolic hormones are integral regulators of female reproductive health and function
Athar, F., Karmani, M., & Templeman, N. M. (2024) · Bioscience Reports · doi:10.1042/bsr20231916 · Cited by 91
“GLP-1 can normalize blood glucose levels in Type 2 diabetes patients [296] and promote weight loss [297].”
BackgroundRibel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F., & Knudsen, L. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02189-1 · Cited by 84
Ørskov, J. J. H. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/clb.61.234.75.85 · Cited by 71
Self-citationGlucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
D’Alessio, D. A., & Vahl, T. P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2004 · Cited by 80
“Because short-term intravenous administration of GLP-1 to humans suppresses consumption of a subsequent lunch (30, 34), it appears that at least some of the satiety effects of GLP-1 are mediated by peripherally, rather than centrally, derived peptide.”
BackgroundPostprandial changes in gut regulatory peptides in gastric bypass patients
Holdstock, C., Zethelius, B., Sundbom, M., Karlsson, F. A., & Engström, B. E. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.157 · Cited by 79
Abbott, C. R., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Broadhead, L. L., Ghatei, M. A., & Bloom, S. R. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803137 · Cited by 77
Effects of Different Dietary Fat Types on Postprandial Appetite and Energy Expenditure
Flint, A., Helt, B., Raben, A., Toubro, S., & Astrup, A. V. (2003) · Obesity Research · doi:10.1038/oby.2003.194 · Cited by 85
Self-citationTronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., Bakizada, Z. M., & Chao, A. M. (2020) · International Journal of Obesity · doi:10.1038/s41366-019-0348-6 · Cited by 74
Vallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00923-1 · Cited by 72
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
Self-citationTobore, T. O. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112560 · Cited by 73
Clinical Impact of Liraglutide as a Treatment of Obesity
Alruwaili, H., Dehestani, B., & le Roux, C. W. (2021) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s276085 · Cited by 93
“more likely to report satiety and fullness and less likely to report hunger.(27) The subjects with obesity who”
BackgroundEmerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
Rosenstock, J., & Zinman, B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280a02f65 · Cited by 78
Factors affecting circulating levels of peptide YY in humans: a comprehensive review
Cooper, J. A. (2014) · Nutrition Research Reviews · doi:10.1017/s0954422414000109 · Cited by 86
Edwards, C. M. B., Cohen, M. A., & Bloom, S. R. (1999) · QJM · doi:10.1093/qjmed/92.1.1 · Cited by 88
Badurdeen, D., Hoff, A. C., Hedjoudje, A., Adam, A., Itani, M. I., Farha, J., Abbarh, S., Kalloo, A. N., Khashab, M. A., Singh, V. K., et al. (2021) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.10.016 · Cited by 72
Montelius, C., Erlandsson, D., Vitija, E., Stenblom, E.-L., Egecioglu, E., & Erlanson-Albertsson, C. (2014) · Appetite · doi:10.1016/j.appet.2014.06.101 · Cited by 72
“We were also interested in measuring the release of GLP-1, a gut hormone promoting satiety ( Flint, Raben, Astrup, & Holst, 1998; Holst, 2007).”
BackgroundRecent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 84
Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 82
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.